Basilea News http://www.basilea.com/ Basilea News en Thu, 29 Jun 2017 16:19:27 +0200 Thu, 29 Jun 2017 16:19:27 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel]]> http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-for-Europe-Russia-Turkey-and-Israel/cbea2c91-3a40-52bc-ad8e-d611023188d9
  • Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
  • Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
  • Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio

  • ]]>
    Wed, 14 Jun 2017 19:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-for-Europe-Russia-Turkey-and-Israel/cbea2c91-3a40-52bc-ad8e-d611023188d9
    <![CDATA[Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Avir-Pharma-Inc-for-Cresemba-isavuconazole-and-Zevtera-ceftobiprole-in-Canada/8bf66ebc-15c4-5087-3111-21223968aa34 Wed, 14 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Avir-Pharma-Inc-for-Cresemba-isavuconazole-and-Zevtera-ceftobiprole-in-Canada/8bf66ebc-15c4-5087-3111-21223968aa34 <![CDATA[Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole]]> http://www.basilea.com/News-and-Media/Basilea-awarded-USD-54-8-million-of-additional-funding-by-BARDA-to-support-phase-3-development-of-ceftobiprole/41105a66-deef-3884-6f26-3eec41605a91 Tue, 13 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-awarded-USD-54-8-million-of-additional-funding-by-BARDA-to-support-phase-3-development-of-ceftobiprole/41105a66-deef-3884-6f26-3eec41605a91 <![CDATA[Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma]]> http://www.basilea.com/News-and-Media/Basilea-announces-clinical-study-agreement-with-Adult-Brain-Tumor-Consortium-to-explore-BAL101553-in-newly-diagnosed-glioblastoma/5371be9d-c4e7-a92a-595c-18e1aadae026
  • The Adult Brain Tumor Consortium (ABTC) is designed to develop more effective treatments for malignant brain tumors. It is funded by the US National Cancer Institute (NCI).
  • The ABTC will conduct a clinical phase 1 study to determine the safety and tolerability of Basilea's novel tumor checkpoint controller BAL101553 in newly diagnosed glioblastoma patients.
  • ]]>
    Mon, 12 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-clinical-study-agreement-with-Adult-Brain-Tumor-Consortium-to-explore-BAL101553-in-newly-diagnosed-glioblastoma/5371be9d-c4e7-a92a-595c-18e1aadae026
    <![CDATA[Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting]]> http://www.basilea.com/News-and-Media/Basilea-announces-presentation-of-interim-phase-1-2a-clinical-data-with-anticancer-drug-candidate-BAL101553-at-ASCO-meeting/4251a9b3-3411-d233-9d95-56921068d60d Tue, 06 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-presentation-of-interim-phase-1-2a-clinical-data-with-anticancer-drug-candidate-BAL101553-at-ASCO-meeting/4251a9b3-3411-d233-9d95-56921068d60d <![CDATA[Basilea names new member of its Extended Management Committee]]> http://www.basilea.com/News-and-Media/Basilea-names-new-member-of-its-Extended-Management-Committee/05c00b12-7a43-6adc-8c20-f12aeb323b02 Fri, 02 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-names-new-member-of-its-Extended-Management-Committee/05c00b12-7a43-6adc-8c20-f12aeb323b02 <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/d41ac13d-7e93-b4d7-2314-bca4f5081474 Thu, 27 Apr 2017 18:31:45 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/d41ac13d-7e93-b4d7-2314-bca4f5081474 <![CDATA[Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections]]> http://www.basilea.com/News-and-Media/Basilea-announces-agreement-with-FDA-on-Special-Protocol-Assessments-for-antibiotic-ceftobiprole-phase-3-clinical-studies-in-bloodstream-and-skin-infections/39fff65b-c97a-73c1-d5e3-745f7e4e58bb
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
  • ]]>
    Fri, 21 Apr 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-agreement-with-FDA-on-Special-Protocol-Assessments-for-antibiotic-ceftobiprole-phase-3-clinical-studies-in-bloodstream-and-skin-infections/39fff65b-c97a-73c1-d5e3-745f7e4e58bb
    <![CDATA[Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab]]> http://www.basilea.com/News-and-Media/Data-presented-at-AACR-meeting-indicate-diverse-tumor-targeting-properties-of-Basileas-BAL101553-and-show-a-combination-potential-with-bevacizumab/94ede521-ce97-ea54-a9ac-84255d5b439f
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
  • ]]>
    Thu, 06 Apr 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Data-presented-at-AACR-meeting-indicate-diverse-tumor-targeting-properties-of-Basileas-BAL101553-and-show-a-combination-potential-with-bevacizumab/94ede521-ce97-ea54-a9ac-84255d5b439f
    <![CDATA[Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors]]> http://www.basilea.com/News-and-Media/Basilea-proposes-Dr-Nicole-Onetto-as-new-member-of-the-Board-of-Directors/1abbab51-c0b7-1375-d0b7-2fb7ca87ca33 Mon, 27 Feb 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-proposes-Dr-Nicole-Onetto-as-new-member-of-the-Board-of-Directors/1abbab51-c0b7-1375-d0b7-2fb7ca87ca33